Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
- 31 July 2010
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 46 (11), 2010-2019
- https://doi.org/10.1016/j.ejca.2010.04.028
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2007
- Mechanisms of cutaneous toxicities to EGFR inhibitorsNature Reviews Cancer, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptorClinical and Experimental Dermatology, 2004
- Issues and progress with protein kinase inhibitors for cancer treatmentNature Reviews Drug Discovery, 2003
- Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225British Journal of Dermatology, 2001
- Targeting the epidermal growth factor receptor for therapy of carcinomasBiochemical Pharmacology, 1996
- Tyrosine Kinase Inhibitors. 9. Synthesis and Evaluation of Fused Tricyclic Quinazoline Analogues as ATP Site Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor ReceptorJournal of Medicinal Chemistry, 1996
- The epidermal growth factor receptor as a target for therapy in breast carcinomaBreast Cancer Research and Treatment, 1994